Document is current

Any future updates will be listed below

Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study

Crossref DOI link: https://doi.org/10.1007/s00259-025-07344-6

Published Online: 2025-05-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark